An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2559-2566

  Wada, Michihiko ^a   Hosotani, Ryo ^a   Lee, Jeon Uk ^a   Doi, Ryuichiro ^a   Koshiba, Takatomo ^a   Fujimoto, Koji ^a   Miyamoto, Yoshiharu ^a   Tsuji, Shoichiro ^a   Nakajima, Sanae ^a   Okuyama, Akira ^b   Imamura, Masayuki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Apoptosis; DNA fragmentation; p53; pRb; Western blotting

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STAINING; TUMOR SUPPRESSOR GENE;

4-BUTYROLACTONE; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL SURVIVAL; CYCLIN A; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; GENES, BCL-2; GENES, P53; HUMANS; KINETICS; MUTATION; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETINOBLASTOMA PROTEIN; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 14444271075     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bartsch D, Shevlin DW, Tung WS, Kisker Q, Wells SA Jr and Goodfellow PJ: Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes-Chromosomes-Cancer 14: 189-195, 1995.
2. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, Beger HG and Korc M: p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer-Lett 69: 151-160, 1993.
3. Evans DB, Frazier ML, Charnsangavej C, Katz RL, Larry L, and Abbruzzese JL: Molecular diagnosis of exocrine pancreatic cancer using a percutaneous technique. Ann-Surg-Oncol 3: 241-246, 1996.
4. Hahn SA, Hoque AT, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, Seymour AB, Weinstein CL, Yeo CJ, Hruban RH, and Kern SE: Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer-Res 56: 490-494, 1996.
5. Hall M and Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68: 67-108, 1996.
6. Huang L, Lang D, Geradts J. Obara T, Klein Szanto AJ, Lynch HT, and Ruggeri BA: Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines. Mol Carcinog 15: 85-95, 1996.
7. Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, and Schmiegel W: Frequent codeletion of p16/MTS 1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 110: 1215-1224, 1996.
8. Sugio K, Gazdar AF, Albores Saavedra J, and Kokkinakis DM: High yields of K-ras mutations in intraductal papillary mucinous tumors and invasive adenocarcinomas induced by N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine in the pancreas of female Syrian hamsters. Carcinogenesis 17: 303-309, 1996.
9. Hunter T: Oncoprotein Networks. Cell 88: 333-346, 1997.
10. Sherr C J: Cancer cell cycles. Science 274: 1672-1677, 1996.
11. Legdeur MC, Bontje PM, Ossenkoppele GJ, Beelen RH, van de Loosdrecht AA, Broekhoven MG, Langenhuijsen MM, Thijsen SF, Hofstee H, and Schuurhuis GJ: The role of BCL-2 and bax protein in monocyte-mediated apoptosis in human leukemic cell lines. Exp-Hematol 24: 1530-1539, 1996.
12. Suzuki S, Li XK, Enosawa S, and Shinomiya T: A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology 89: 518-523, 1996.
13. Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, and Newcomb EW: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 12: 1055-1062, 1996.
14. Oltvai ZN, Milliman CL, and Korsmeyer SJ: bcl-2 heterodimerizes m vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
15. Miyashita T, Harigai M, Hanada M, and Reed JC: Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131-3135, 1994.
16. Lee J-U, Hosotani R, Wada M, Doi R, Koshiba T, Fujimoto K, Miyamoto Y, Mori C, Nakamura N, Shiota K, and and Imamura M: Mechanism of apoptosis induced by Cisplatin and VP-16 in PANC-1 cells. Anticancer Res 17: 3445-3450, 1997.
17. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, and Liebermann D: Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 9: 1791-1798, 1994.
18. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
19. Liebermann DA, Hoffman B, and Steinman RA: Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 11: 199-210, 1995.
20. Kitagawa M, Higashi H, Takahashi IS, Okabe T, Ogino H, Taya Y, Nlshimura N, and and Okuyama A: A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. Oncogene 9: 2549-2557, 1994.
21. Kitagawa M, Okabe T, Ogino H, Matsumoto H, Takahashi IS, Kokubo T, Higashi H, Saitoh S, Taya Y, Yasuda H, Ohba Y, Nishimura S, Tanaka N, and Okuyama A: Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 8: 2425-2432, 1993.
22. Shibata Y, Nishimura S, Okuyama A, and Nakamura T: p53-independent induction of apoptosis by cyclin-dependent kinase Inhibition. Cell Growth and Differentiation 7: 887-891, 1996.
23. Fan G, Ma X, Kren BT, and Steer CJ: The retinoblastoma gene product inhibits TGF-betal induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells. Oncogene 12: 1909-1919, 1996.
24. Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio AF, Bursch W, and Schulte Hermann R: Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc Natl Acad Sci USA 89: 5408-5412, 1992.
25. Doi R, Wada M, Hosotani R, Lee J-U, Koshiba T, Fujimoto K, Mori C, Nakamura N, Shiota K, and Imamura M: Role of apoptosis in duct obstruction-induced pancreatic involution in rats. Pancreas 14: 39-46, 1997.
26. Sumi S, Beauchamp RD, Townsend JCM, Uchida T, Murakami M, Rajaraman S, Ishizuka J, and Thompson JC: Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterol 103: 982-989, 1992.
27. Berrozpe G, Schaeffer J, Peinado MA, Real FX, and Perucho, M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 58: 185-191, 1994.
28. Pines J: Cyclins and their associated cyclin-dependent kinases in the human cell cycle. Biochem Soc Trans 21: 921-925, 1993.
29. Akiyama T, Ohuchi T, Sumida S, Matsumoto K, and Toyoshima K: Phosphorylation of the retinoblastoma protein by cdk2. Proc Natl Acad Sci USA 89: 7900-7904, 1992.
30. Elledge SJ and Spottswood MR: A new human p34 protein kinase, CDK2, identified by complementation of a cdc28 mutation in Saccharomyces cerevisiae, is a homolog of Xenopus Eg 1. EMBO-J. 10: 2653-2659, 1991.
31. Girard F, Strausfeld U, Fernandez A, and Lamb NJ: Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67: 1169-1179, 1991.
32. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
33. Pietenpol JA, Tokino T, Thiagalingam S, el Deiry WS, Kinzler KW, and Vogelstein B: Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 91: 1998-2002, 1994.
34. Ory K, Legros Y, Auguin C, and Soussi T: Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13: 3496-3504, 1994.
35. Crook T, Marston NJ, Sara EA, and Vousden KH: Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79: 817-827, 1994.
36. Ludwig RL, Bates S, and Vousden KH: Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Molecular and Cellular Biology 16: 4952-4960, 1996.
37. Lee J-U, Hosotani R, Wada M, Koshiba F, Fujimoto K, Miyamoto Y, Doi R, Nishimura Y and and Imamura M: Relationship between oncoproteins (Bax, bcl-2 and Bcl-X) and cellular susceptability to radiation in pancreatic cancer cells, Gastroenterology 112: A601, 1997.